FDA Approves New Treatment for HER2-positive Breast Cancer

The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating certain patients with breast cancer on Dec. 20, 2019. Specifically, it was approved for treating adults who have unresectable or metastatic HER2-positive breast cancer that has progressed despite treatment with two or more other HER2-targeted treatment regimens after the diagnosis of metastatic disease.

Read More